Opinion|Videos|October 21, 2024
Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC
Key Takeaways
- CREST, POTOMAC, KEYNOTE, and ALBAN trials investigate PD-1/PD-L1 inhibitors for BCG-naive bladder cancer patients, focusing on efficacy and safety.
- Routes of administration vary, with some trials using intravenous delivery and others exploring intravesical administration to optimize therapeutic outcomes.
Panelists discuss the specific PD-1/PD-L1 inhibitors currently being investigated in phase 3 trials for BCG-naive patients with non–muscle-invasive bladder cancer (NMIBC), including CREST, POTOMAC, KEYNOTE, and ALBAN, detailing how routes of administration and durations of therapy vary among these agents and emphasizing the significance of differences in control arms within the trials.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you explain in detail which PD-1/PD-L1 inhibitors are being investigated in phase 3 trials for BCG-naive patients? [describe CREST, POTOMAC, KEYNOTE, ALBAN,] (PMID 38849286; DOI
10.1016/S0302-2838(24)01302-2 ) - How do the routes of administration and durations of therapy differ among the agents/trials?
Bedke 2023 Steinberg 2024
Advertisement
Related to this article
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.
Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
2
Pasritamig combination yields 73% PSA response rate in phase 1 mCRPC study
3
FAQ: ASTRO guideline on hypofractionated radiation therapy for localized prostate cancer
4
Q&A: Suzanne B. Merrill, MD, FACS, on perioperative therapy in MIBC
5